---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-001175"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:35:48.380113+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q2 revenue $28.3M (-43% YoY); net loss narrows to $9.2M; CF data due Sep

## Summary
- Revenue fell 43% YoY to $28.3M, driven by lower CSL collaboration activity and KOSTAIVE amortization.
- Net loss improved to $9.2M ($0.34 loss per share) from $17.2M loss in Q2 2024.
- Operating expenses dropped to $39.9M from $71.0M, mainly on lower KOSTAIVE and flu program costs.
- Cash and restricted cash $253.4M, extended runway into 2028.
- ARCT-032 CF Phase 2 interim data for 9 participants due Sep 2025; KOSTAIVE UK MAA decision expected Sep 2025.

## SEC filing metadata
- accession: 0001193805-25-001175
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380525001175/0001193805-25-001175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380525001175/e664773_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-001175
- JSON: https://secwatch.observer/filing/0001193805-25-001175.json
- Plain text: https://secwatch.observer/filing/0001193805-25-001175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.